by upagency | Feb 28, 2021 | Press Releases
On International Rare Diseases Day, we’d like to introduce 2N Pharma’s approach to finding treatments for #ALS and other neurodegenerative disorders. Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease or Motor Neurone Disease (MND) is a rapidly...
by upagency | Feb 24, 2021 | Press Releases
On the International Day of Women and Girls in Science, Anne Skøttrup Mørkholt, 2N Pharma’s Project Manager talked about her career to date in bio-pharmacology and her role in the search for cures to incurable diseases. What was it that made you...
by Web Developer | Oct 27, 2020 | Press Releases
Novo Nordisk Foundation’s innovation initiative, BioInnovation Institute (BII) has awarded EUR 14 million to eight early-stage life science start-ups and research projects. BII has accepted five early-stage start-up companies into the Creation House life science...
by Web Developer | Oct 27, 2020 | Press Releases
The therapeutics start-up 2N Pharma is one of the five new companies in BioInnovation Institute’s Creation House program. The start-up is developing an alternative to today’s treatment of amyotrophic lateral sclerosis (ALS) and is building its case on 10...
by Web Developer | Oct 27, 2020 | Press Releases
The Bioinnovation Institute (BII) have accepted biotech start-up 2N Pharma into its Creation House program awarding the start-up EUR 1.3 million to develop its first in class treatment for the neurodegenerative disease ALS (amyotrophic lateral sclerosis). Also called...
Recent Comments